Why Has My Weight Loss Plateaued — and What Can I Do About It?

What a weight-loss plateau really means

A plateau occurs when your weight stops declining despite continued medication use, consistent eating habits, and regular activity. On GLP-1 therapy, most people experience meaningful weight loss in the first several months, followed by a period when the scale seems to stall or slow dramatically. This is not a sign the medication has stopped working, and it is not a failure on your part.

Clinically, a plateau is generally defined as no significant change in weight over four or more consecutive weeks despite adherence to the treatment plan. It is one of the most predictable phases of any obesity treatment — a biological event, not a behavioral one.

The science behind the plateau: metabolic adaptation and set-point defense

The most important concept behind a plateau is metabolic adaptation, also called adaptive thermogenesis. When body weight falls, the body does not simply burn fewer calories because it is smaller — it actively reduces its energy expenditure as a defense against further weight loss.

This coordinated biological response includes several components:

• Lower resting metabolic rate: Energy burned at rest drops beyond what is explained by loss of body mass alone.
• Reduced non-exercise activity thermogenesis (NEAT): The energy spent in everyday movement — fidgeting, standing, and casual walking — decreases without conscious awareness.
• Hormonal shifts: Levels of hormones that regulate hunger, including leptin, change in ways that increase appetite and slow metabolism.

This is often called set-point defense — the body's tendency to resist deviation from a familiar weight range. GLP-1 receptor agonists blunt some of these compensatory hunger signals, which is part of why they outperform diet alone, but they do not fully override metabolic adaptation. A plateau is the set-point pushing back.

The typical GLP-1 weight-loss curve

Clinical trial data from the landmark STEP program (semaglutide) and SURMOUNT program (tirzepatide) illustrate a consistent pattern: weight loss is most rapid in the first few months, then progressively slows as individuals approach their new lower weight. This expected flattening of the curve is visible across both programs and reflects the body reaching a new defended equilibrium — not treatment failure.

In practice, early weeks feel dramatic while later months feel slower, even when real progress continues. Importantly, body-composition improvements — including reductions in visceral fat and changes in metabolic markers such as blood pressure and fasting glucose — often continue even when the scale moves little. Looking beyond body weight to waist circumference, energy levels, and lab values can give a more complete picture of what treatment is doing for your health.

Has your dose been fully titrated?

GLP-1 medications are started at a low dose and gradually increased — a process called titration — to reach the level where appetite suppression and metabolic effects are most pronounced while side effects remain manageable. If you are experiencing a plateau at an early or intermediate dose, you may not yet be at your therapeutically effective dose, and further titration may resume progress.

This is one of the first questions worth exploring with your Nuv provider. Confirming whether you are still in the titration phase or already at the maximum approved dose changes what the plateau means clinically and what next steps make sense.

If you are using a compounded semaglutide or tirzepatide preparation, be aware that compounded versions of these medications are not FDA-approved and may differ in formulation, potency, or absorption from the branded products studied in clinical trials. Discuss this with your provider if you have questions about your current regimen.

Protecting muscle mass and supporting your metabolism

Metabolic adaptation is worsened when weight loss includes significant muscle loss, because muscle is the body's most metabolically active tissue. Protecting lean mass during a plateau is one of the most actionable steps available to you.

• Prioritize dietary protein: Protein supports muscle preservation during calorie restriction and has a higher thermic effect than carbohydrates or fat, meaning the body uses more energy to digest it. Most obesity-medicine clinicians recommend emphasizing protein at every meal.
• Add or maintain resistance training: Strength exercise is the most effective intervention for preserving and rebuilding muscle. Even two sessions per week can make a meaningful difference to your metabolic rate and body composition over time.
• Protect sleep: Consistently poor or short sleep elevates cortisol, disrupts hunger-regulating hormones, and is associated with greater lean-mass loss during weight loss.
• Manage chronic stress: Elevated cortisol promotes fat storage — particularly visceral fat — and can partially blunt the appetite-suppressing effects of GLP-1 therapy.
• Review your food intake honestly: As GLP-1 side effects ease and appetite partially returns over months of treatment, calorie intake often drifts upward gradually. Revisiting a food log, even briefly, can reveal patterns that are easy to overlook.

When a plateau is expected versus when to reassess with your provider

Not every plateau requires clinical intervention — some represent the body reaching a healthy new equilibrium. Knowing which situation applies helps guide the right response.

A plateau is expected when:

• You are still in the dose-titration phase and have not yet reached your effective dose.
• You have been losing weight for several months and have recently reached a new stable weight.
• The scale is stable, but health markers, energy, or body composition continue to improve.

A plateau warrants a provider conversation when:

• You have been at your full therapeutic dose for more than eight to twelve weeks with no movement and no improvement in health markers.
• Medication side effects are significantly affecting your adherence or quality of life.
• You are uncertain about correct injection technique, storage, or timing.
• A new medication, health event, or major stressor has coincided with the stall.
• Mood, disordered eating patterns, or other factors may be affecting your relationship with food or your adherence.

Realistic expectations and self-compassion

Obesity is a chronic, complex condition with strong genetic and biological underpinnings — not a reflection of effort or personal character. GLP-1 medications represent a meaningful advance in treatment, and they work within your biology, not in spite of it. A plateau is a predictable part of the natural trajectory of this therapy.

Sustainable progress on GLP-1 therapy is measured in months and years, not weeks. Research consistently shows that people who do best over the long term maintain their treatment plan, stay connected to their care team, protect their muscle mass, and hold expectations that are honest rather than perfectionist. If you have lost weight, improved metabolic markers, and held those gains — that is real, clinically meaningful success, even when the scale is temporarily still.